BetterLife Pharma

02/10/2022

BetterLife Pharma’s, Without the , is a potential for solving two key obstacles in the fight against the global footprint. Pharma’s CEO Dr. Ahmad Doroudian discusses how the company is positioned well to address the controlled substance hurdle and the scalability challenge that exist.

For a deeper look, more can be found at CFN Media Group’s article. https://www.cannabisfn.com/psychedelic-therapy-without-the-hallucinations-interview-with-betterlife-pharma/

02/09/2022

The peer-reviewed, scientifically proven from medicine is an exciting development spurring great changes to mental healthcare, globally. It is our hope that this area of will continue to expand, from and the US so other nations follow this example and embrace psychedelic treatment options that are safe, effective, and affordable. Visit abetterlifepharma.com for more info.

02/08/2022

The Canadian Association (CMHA) reports that 20% of Canadians experience a mental health problem or illness every year. The CHMA notes that mental illness costs the Canadian social and healthcare system nearly $80 billion in 2021. BetterLife Pharma is a biotechnology company developing patient-friendly for the global mental health . Visit abetterlifepharma.com for details.

02/07/2022

COVID-19 and the subsequent lockdown environment coupled with the growing societal acceptance and regulatory acceptance openness of psychedelics, believes that the is on the cusp of realizing its true potential. With this and this and more, $BETR: CNX can be an attractive option for savvy, progressive who are looking to gain access to this burgeoning promising sector, on the ground floor. Visit abetterlifepharma.com for more info.

02/04/2022

Psilocybin is a prodrug found in nature in more than 200 species of fungi. The tryptamine alkaloid has hallucinogenic, anxiolytic, and psychoactive properties. activates and binds with high affinity to the 5-HT2A serotonin receptors in the CNS, copying the effects of serotonin (5-HT). (Source: https://buff.ly/3HsxmBd). Visit https://abetterlifepharma.com/ for more details.

02/03/2022

In December 2020, the World Health Organization (WHO) stated an estimated 264 million people suffer from . Unsurprisingly, depression is anticipated to account for the largest portion of this segment in the psychedelic market during the forecast period. Growing evidence has suggested could treat depression effectively. has assembled a highly experienced scientific and management team that has clinical, commercial, product development and financial experience to address unmet needs within the mental health industry. (Source: https://buff.ly/2W44SXh). Visit https://abetterlifepharma.com/ for more details.

02/02/2022

A study conducted on mice determined that one dose of immediately increased neural connections in the brains. Doctors believe this helps the brain "reorganize and adapt" to different situations, improving response time. BETR-001 is a non-hallucinogenic second-generation Lysergic Acid Diethylamide (“L*D”) derivative molecule that mimics the projected therapeutic potential of *D in the treatment of disorders such as , post-traumatic stress disorder (“PTSD”), and migraines. (Source: Yale University)

02/01/2022

According to a ResearchAndMarkets.com report, the market is expected to grow at a robust rate of 14.5% CAGR during the forecast period and reach a value of $6.33 billions in 2026 from $3.210 billions in 2021 as there is a large unmet need for treatment driving the adoption of psychedelic drugs. Visit https://abetterlifepharma.com/ for more details.

01/31/2022

North America is predicted to remain the largest market in the space due to a surge of clinical trials, massive , regulatory support, and widespread public awareness. BetterLife is an emerging biotech company focused on the development and commercialization of 2nd-generation psychedelic analogs for the treatment of neuropsychological disorders ready to capitalize on this space. Visit for more details.

We're a biotech company creating & clinically validating an evolving IP portfolio of novel molecules & drug delivery mechanisms for clinical trials & comm

01/27/2022

Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the medical cost of mental health conditions is estimated to rise to $6 trillion by 2030. is focused on developing second generation compounds, addressing unmet needs within the , wellness and anti-aging industries. Visit https://abetterlifepharma.com/ for details.

01/25/2022

BetterLife Pharma Inc. (BetterLife) sat down with CFN Enterprises to discuss the company's recent successes and forthcoming achievements as it gets ready for a busy 2022.

BetterLife’s Chief Executive Officer, Dr. Ahmad Doroudian and CFN Enterprises's Robin Lefferts looked at some key topoics that differentiate BetterLife in its space and within the greater biotech domain. Their discourse covered questions like 1) how is BetterLife positioned today? 2) what recent developments has it achieved? and 3) what kind of catalysts can the market expect from it, looking ahead?

These and other points are expanded on, in the full interview, found by clicking on this link below:
https://www.cannabisfn.com/psychedelic-treatment-for-depression-moving-toward-clinical-trials/

01/25/2022

BetterLife Pharma made the top 5 developments for the week of January 17 on the (TDR). has obtained positive results from an in vivo oral bioavailability and food-effect pharmacokinetic (PK) study on BETR-001 in beagle dogs. Read the full report here: https://buff.ly/3IS0EJZ